Key terms
About CAPR
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CAPR news
Mar 12
2:01am ET
Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
Mar 06
8:40am ET
Capricor Therapeutics presents results from HOPE-2 extension study
Mar 05
12:55pm ET
Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress
Mar 01
6:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)
Feb 29
4:21pm ET
Capricor Therapeutics reports Q4 EPS (2c), consensus (9c)
Feb 27
8:37am ET
Capricor announces company granted in-person Type-B meeting with FDA
Feb 20
8:48am ET
Capricor Therapeutics announces manufacturing scale-up of CAP-1002 production
Jan 26
7:41am ET
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), CVRx (CVRX) and Capricor Therapeutics (CAPR)
Jan 24
9:17am ET
Capricor Therapeutics, NIH collaborate for trial of StealthX vaccine
Jan 05
7:10am ET
Capricor initiated with an Overweight at Cantor Fitzgerald ahead of Phase 3 data
Jan 05
6:14am ET
Capricor Therapeutics initiated with an Overweight at Cantor Fitzgerald
Dec 12
12:55pm ET
Capricor Therapeutics: A Strong Buy on Back of Promising Phase 3 Progress and Strategic Financial Health
No recent news articles are available for CAPR
No recent press releases are available for CAPR
CAPR Financials
Key terms
Ad Feedback
CAPR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CAPR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range